Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates

USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. After announcing positive interim data with notable improvements in estimated median overall survival after experimental treatment, Candel Therapeutics, Inc. (NASDAQ: CADL) received FDA orphan drug designation in pancreatic cancer for its CAN-2409 in combination with valacyclovir and standard-of-care (SOC) chemoradiation followed by resection. VANCOUVER, BC, May 23, 2024 /PRNewswire/ -- USA News Group – Known as one of the deadliest cance ...